Philip D. Gregory Sells 850 Shares of bluebird bio Inc (NASDAQ:BLUE) Stock

bluebird bio Inc (NASDAQ:BLUE) insider Philip D. Gregory sold 850 shares of the company’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $101.20, for a total transaction of $86,020.00. Following the sale, the insider now directly owns 30,692 shares of the company’s stock, valued at approximately $3,106,030.40. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of NASDAQ BLUE traded up $0.22 during mid-day trading on Monday, reaching $99.65. 368,049 shares of the company’s stock were exchanged, compared to its average volume of 543,996. The firm has a market capitalization of $5.50 billion, a price-to-earnings ratio of -9.33 and a beta of 2.28. The company has a debt-to-equity ratio of 0.11, a quick ratio of 8.02 and a current ratio of 8.02. bluebird bio Inc has a 52-week low of $87.49 and a 52-week high of $163.43. The company’s 50-day moving average is $117.68 and its 200-day moving average is $132.45.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($3.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.04) by ($0.51). The company had revenue of $13.30 million during the quarter, compared to analysts’ expectations of $13.13 million. bluebird bio had a negative net margin of 1,158.04% and a negative return on equity of 35.90%. The firm’s quarterly revenue was up 68.4% on a year-over-year basis. During the same quarter last year, the firm posted ($2.91) earnings per share. As a group, equities analysts predict that bluebird bio Inc will post -13.22 earnings per share for the current fiscal year.



Several institutional investors and hedge funds have recently made changes to their positions in BLUE. Aperio Group LLC lifted its holdings in shares of bluebird bio by 4.4% in the 2nd quarter. Aperio Group LLC now owns 12,447 shares of the biotechnology company’s stock worth $1,583,000 after acquiring an additional 530 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in shares of bluebird bio by 6.5% during the second quarter. Commonwealth Equity Services LLC now owns 3,793 shares of the biotechnology company’s stock worth $482,000 after buying an additional 230 shares during the period. MayTech Global Investments LLC increased its stake in shares of bluebird bio by 445.7% during the first quarter. MayTech Global Investments LLC now owns 30,182 shares of the biotechnology company’s stock worth $4,749,000 after buying an additional 24,651 shares during the period. Nikko Asset Management Americas Inc. raised its holdings in bluebird bio by 37.5% in the second quarter. Nikko Asset Management Americas Inc. now owns 133,786 shares of the biotechnology company’s stock valued at $17,018,000 after acquiring an additional 36,485 shares in the last quarter. Finally, Winslow Evans & Crocker Inc. raised its holdings in bluebird bio by 5.0% in the second quarter. Winslow Evans & Crocker Inc. now owns 4,200 shares of the biotechnology company’s stock valued at $536,000 after acquiring an additional 200 shares in the last quarter.

A number of research analysts have weighed in on BLUE shares. Morgan Stanley decreased their target price on shares of bluebird bio from $143.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 6th. Gabelli reaffirmed a “buy” rating on shares of bluebird bio in a report on Friday, July 19th. BidaskClub downgraded bluebird bio from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 28th. JPMorgan Chase & Co. reissued a “buy” rating and set a $195.00 price objective on shares of bluebird bio in a research note on Thursday, June 13th. Finally, Piper Jaffray Companies set a $120.00 target price on bluebird bio and gave the company a “hold” rating in a report on Friday, June 14th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. bluebird bio currently has a consensus rating of “Buy” and an average price target of $154.13.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

Read More: Monthly Dividend Stocks Can Provide Solid Income

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.